ERBB2 and neoplasm: Specifically, the patients had incidences of Scarf Bloom Richardson (SBR) grade 3 (77.1% vs. 46.5%; p < 0.001), Ki67 > 30% (86.0% vs. 52.1%; p = 0.0002), and clinical lymph nodes (cN+) (89.9% vs. 81.0%; p = 0.047) more frequently than patients with HR+ and/or HER2+ tumours.